Spondyloarthritis & psoriatic arthritis
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry
Authors' conclusion
Considering the recent ASAS definition of early axSpA, TNFi effectiveness seems comparable in early versus established disease.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) in the Swiss Clinical Quality Management registry with data on duration of axial symptomsfirst tumour necrosis factor inhibitor (TNFi): 250 early, 874 established
- Participants
- 3,064 patients
- Exposure
- First TNFi in early axSpA vs established axSpA
- Early axSpAn = 658
- Established axSpAn = 2,406reference
- Outcome
- TNFi drug retention
Methodological detailsobservational registry, multiple-adjusted Cox proportional hazards models, adjusted logistic regression, Results confirmed in the population fulfilling the ASAS classification criteria
- Observational registry
- Multiple-adjusted Cox proportional hazards models
- Adjusted logistic regression
- Results confirmed in the population fulfilling the ASAS classification criteria
Main finding
As reported in the abstract
First TNFi drug retention, early vs established axSpA
- Comparable TNFi retention in early vs established disease
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| ASAS40 response · 1 yearAdjusted | 1.09 (0.67–1.78) | |
| 0.512Odds ratio (log scale) |
ASAS40 response · 1 year
- Similar in the two groups
Patient characteristics
- Sex, disease activity, function and health-related quality of life comparable
- Established disease: older, more prevalent axial radiographical damage, higher impairment of mobility
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. RMD Open. Published 1 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →